Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-three ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $1,052.90.

REGN has been the subject of a number of recent analyst reports. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Finally, Bank of America reiterated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. &PARTNERS acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $627,000. Cornerstone Wealth Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.9% during the 2nd quarter. Cornerstone Wealth Group LLC now owns 3,718 shares of the biopharmaceutical company’s stock valued at $3,908,000 after buying an additional 104 shares during the period. Catalina Capital Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 20.8% during the 2nd quarter. Catalina Capital Group LLC now owns 302 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 52 shares in the last quarter. Premier Path Wealth Partners LLC increased its stake in shares of Regeneron Pharmaceuticals by 11.1% in the second quarter. Premier Path Wealth Partners LLC now owns 620 shares of the biopharmaceutical company’s stock worth $651,000 after acquiring an additional 62 shares during the last quarter. Finally, Everhart Financial Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 14.8% in the second quarter. Everhart Financial Group Inc. now owns 550 shares of the biopharmaceutical company’s stock worth $578,000 after acquiring an additional 71 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $714.62 on Thursday. Regeneron Pharmaceuticals has a 12-month low of $712.30 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market capitalization of $78.53 billion, a price-to-earnings ratio of 17.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.08. The business has a 50 day simple moving average of $833.09 and a 200 day simple moving average of $998.86.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.